Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease

被引:207
作者
Peng, SY
Wuu, J
Mufson, EJ
Fahnestock, M
机构
[1] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON L8N 3Z5, Canada
[2] Rush Univ, Ctr Med, Dept Neurol Sci, Chicago, IL 60612 USA
[3] Rush Univ, Ctr Med, Alzheimers Dis Ctr, Chicago, IL 60612 USA
关键词
Alzheimer disease; cholinergic; nerve growth factor (NGF); neurodegeneration; neurotrophic factor; parietal cortex; western blotting;
D O I
10.1093/jnen/63.6.641
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Nerve growth factor (NGF) is critical for the regulation, differentiation, and survival of basal forebrain cholinergic neurons that degenerate in the late stage of Alzheimer disease (AD). The precursor of NGF (proNGF) is the predominant form of NGF in brain and is increased in end stage AD. To determine whether this increase in proNGF is an early or late change during the progression of cognitive decline, we used Western blotting to measure the relative amounts of proNGF protein in the parietal cortex from subjects clinically classified with no cognitive impairment (NCI; n = 20), mild cognitive impairment (MCI it = 20), or mild to moderate AD (n = 19). We found that proNGF increased during the prodromal stage of AD. The amount of proNGF protein was 1.4-fold greater in the MCI group as compared to NCI, and was 1.6-fold greater in mild-moderate AD as compared to NCI, similar to our previous findings of a 2-fold increase in end stage AD. There was a negative correlation between proNGF levels and Mini Mental Status Examination (MMSE) score, demonstrating that the accumulation of proNGF is correlated with loss of cognitive function. These findings demonstrate that proNGF levels increase during the preclinical stage of AD and may reflect an early biological marker for the onset of AD.
引用
收藏
页码:641 / 649
页数:9
相关论文
共 74 条
[1]   Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype [J].
Allen, SJ ;
MacGowan, SH ;
Tyler, S ;
Wilcock, GK ;
Robertson, AGS ;
Holden, PH ;
Smith, SKF ;
Dawbarn, D .
NEUROSCIENCE LETTERS, 1997, 239 (01) :33-36
[2]  
[Anonymous], 1997, Neurobiol Aging, V18, pS1
[4]   Neurotrophins differentially enhance acetylcholine release, acetylcholine content and choline acetyltransferase activity in basal forebrain neurons [J].
Auld, DS ;
Mennicken, F ;
Day, JC ;
Quirion, R .
JOURNAL OF NEUROCHEMISTRY, 2001, 77 (01) :253-262
[5]   Natural history of mild cognitive impairment in older persons [J].
Bennett, DA ;
Wilson, RS ;
Schneider, JA ;
Evans, DA ;
Beckett, LA ;
Aggarwal, NT ;
Barnes, LL ;
Fox, JH ;
Bach, J .
NEUROLOGY, 2002, 59 (02) :198-205
[6]   Apolipoprotein E ε4 allele, AD pathology, and the clinical expression of Alzheimer's disease [J].
Bennett, DA ;
Wilson, RS ;
Schneider, JA ;
Evans, DA ;
Aggarwal, NT ;
Arnold, SE ;
Cochran, EJ ;
Berry-Kravis, E ;
Bienias, JL .
NEUROLOGY, 2003, 60 (02) :246-252
[7]   NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES [J].
BRAAK, H ;
BRAAK, E .
ACTA NEUROPATHOLOGICA, 1991, 82 (04) :239-259
[8]   Neurotrophins: To cleave or not to cleave [J].
Chao, MV ;
Bothwell, M .
NEURON, 2002, 33 (01) :9-12
[9]  
Chen KS, 1997, J NEUROSCI, V17, P7288
[10]   Characterization of nerve growth factor precursor protein expression in rat round spermatids and the trophic effects of nerve growth factor in the maintenance of Sertoli cell viability [J].
Chen, Y ;
Dicou, E ;
Djakiew, D .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1997, 127 (02) :129-136